Patent details
LUC00176
Product Name:
Saxagliptine et dapagliflozine
Basic Information
- Publication number:
- LUC00176
- Type:
- SPC
- SPC Type:
- Medical
- Basic Patent Number:
-
EP087326955
- Legal Status:
- Inactive
- Application number:
- LUC00176
- First applicant's nationality:
- Procedural language:
- French
Marketing Authorization
- Marketing Authorization Number:
- EU/1/16/1108
- Marketing Authorization Type:
-
- Marketing Authorization Date:
- 19/07/2016
- Marketing Authorization Status:
- Accepted
- Marketing Authorization Country:
- Luxembourg (LU)
Dates
- Filing date:
- 31/08/2020
- First Marketing Authorization date:
- 19/07/2016
- Grant date:
- 29/04/2022
- Activation date:
- Publication date:
- 03/09/2020
- Lapsed date:
- Expiration date:
- Renunciation date:
- Revocation date:
- Annulment date:
- Basic SPC Expiration:
- 19/07/2031
- SPC Extension Expiration:
- 19/07/2031
- Rejection date:
- Withdrawal date:
Owner
- From:
- 31/08/2020
-
-
- Name:
- AstraZeneca AB
- Address:
- Forskargatan 18, 151 85 Södertälje, Sweden (SE)
Agent
- Name:
- MARKS & CLERK LLP
- From:
- 31/08/2020
- Address:
- BP 1775, 1017, LUXEMBOURG, Luxembourg (LU)
- To:
Publication
Bulletin
1
- Bulletin Heading:
- SPC1
- Bulletin edition number:
- 2020/11
- Publication date:
- 02/10/2020
- Description:
- Section C : Published requests for Supplementary Protection Certificates – I1 publication
2
- Bulletin Heading:
- SPC2
- Bulletin edition number:
- 2022/06
- Publication date:
- 03/05/2022
- Description:
- Section D : Granted supplementary protection certificates – I2 publication
Annual Fees
- Annual Fee Due Date:
- 31/03/2028
- Annual Fee Number:
- 21
- Annual Fee Amount:
- 410 Euro
- Expected Payer:
-
- Last Annual Fee Payment Date:
-
- Last Annual Fee Paid Number:
-
- Payer:
-